In conclusion, an ultralow-risk MammaPrint 70-gene signature test result can help avoid systemic overtreatment in postmenopausal patients with node-negative, estrogen receptor-positive, HER2-negative breast cancer and has the potential to improve shared decision making by clinicians and patients regarding limited or no adjuvant endocrine therapy. Here, ERBB2 is linked to breast cancer.